AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23097397
Drug: Pigs on
RxNorm normalized name: guinea pig dander
DrugBank: Cavia porcellus dander (DB11019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pigs on the Bt/Bt treatment
Trial: 20394489
Drug: Mometasone cream
RxNorm normalized name: mometasone Topical Cream
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone cream (0.1%) once daily
Trial: 20394489
Drug: Pimecrolimus cream
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimecrolimus cream (1%) twice daily
Trial: 15101860
Drug: Pre group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre group (promethazine 0.1 mg kg(‐1) before anaesthesia)
Trial: 15101860
Drug: Post group
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post group (saline before anaesthesia, promethazine 0.1 mg kg(‐1) postoperatively)
Trial: 11273253
Drug: Polyunsaturated phosphatidyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyunsaturated phosphatidyl choline (PPC) 350 mg thrice daily for 6 to 8 weeks
Trial: 18515458
Drug: Lithium-valproate combination
RxNorm normalized name: valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium-valproate combination
Trial: 11688904
Drug: Interferon-alpha monotherapy
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha monotherapy
Trial: 3300975
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg isosorbide 5‐mononitrate
Trial: 3300975
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg isosorbide 5‐mononitrate
Trial: 3300975
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg isosorbide 5‐mononitrate
Trial: 31488733
Drug: Noradrenergic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenergic and serotonergic antidepressants with 100 mg acetylsalicylic acid (ASA)
Trial: 31488733
Drug: Noradrenergic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenergic and serotonergic antidepressants without 100 mg acetylsalicylic acid (ASA)
Trial: 31488733
Drug: Noradrenergic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenergic and serotonergic antidepressants (both with and without ASA)
Trial: 20338501
Drug: Bone marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow mononuclear cell therapy (BMC therapy)
Trial: 20338501
Drug: Higher numbers
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher numbers of RBCs in BMC preparation
Trial: 17403067
Drug: First offender
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First offender incarceration and treatment program
Trial: 17403067
Drug: First offender
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First offender incarceration and treatment program (for ASPD participants)
Trial: 17403067
Drug: First offender
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First offender incarceration and treatment program (relative to control)
Trial: 15831714
Drug: Naloxone (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (80 microg/kg iv bolus injection)
Trial: 3043355
Drug: doxycycline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxycycline (200 mg once daily)
Trial: 29445655
Drug: Nonextensible lumbosacral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonextensible lumbosacral orthosis (LSO) in addition to routine physical therapy
Trial: 25458446
Drug: Ultrasound and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound and electrical stimulator guided obturator nerve block using 5% phenol in aqueous solution
Trial: 20817628
Drug: Exposure to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to salt based wood protection agents
Trial: 19273451
Drug: Abatacept 2
RxNorm normalized name: abatacept 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept 2 mg/kg
Trial: 12945222
Drug: Bisoprolol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 2.5 mg/HCTZ 6.25 mg
Trial: 12945222
Drug: Bisoprolol 5
RxNorm normalized name: bisoprolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 5 mg/HCTZ 6.25 mg
Trial: 12945222
Drug: Continuation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation with Bisoprolol 2.5 mg/HCTZ 6.25 mg for 4 more weeks
Trial: 12945222
Drug: Up-titration to
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up-titration to Bisoprolol 5 mg/HCTZ 6.25 mg
Trial: 8373709
Drug: Yohimbine (alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (alpha 2‐adrenoceptor antagonist)
Trial: 8373709
Drug: Standing after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standing after yohimbine administration
Trial: 25775165
Drug: Metformin arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin arm
Trial: 26588822
Drug: Instruction with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instruction with sham treatment (peppermint essence vapor)
Trial: 26588822
Drug: Conditioning with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditioning with sham treatment (peppermint essence vapor)
Trial: 26588822
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of instruction and conditioning
Trial: 21193234
Drug: Effective radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effective radiation dose for MDCT‐XTe
Trial: 21193234
Drug: Effective radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effective radiation dose for MDCT‐XT
Trial: 21193234
Drug: Effective radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effective radiation dose for MDCT‐Helical
Trial: 15943841
Drug: famotidine 20
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine 20 mg b.d. (n = 48)
Trial: 15943841
Drug: omeprazole once
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: omeprazole once daily (n = 50)
Trial: 6280836
Drug: BCG immunotherapy
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG immunotherapy (1 vial of high viability Pasteur BCG by scarification technique on days 8 and 15 of each 21-28 day treatment cycle)
Trial: 6280836
Drug: BCG immunotherapy
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG immunotherapy (for patients who responded and survived longer than one year)
Trial: 6280836
Drug: No BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No BCG immunotherapy (for patients who responded and survived longer than one year)
Trial: 25421470
Drug: Micafungin 2
RxNorm normalized name: Micafungin
DrugBank: Micafungin (DB01141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micafungin 2 mg/kg/day
Trial: 25421470
Drug: Micafungin 1
RxNorm normalized name: micafungin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin 1 mg/kg/day
Trial: 25421470
Drug: Micafungin 3
RxNorm normalized name: Micafungin
DrugBank: Micafungin (DB01141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micafungin 3 mg/kg/day
Trial: 21851025
Drug: Infusion therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion therapy controlled by transesophageal dopplerography (Cardio Q apparatus)
Trial: 21851025
Drug: Infusion therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion therapy assessed clinically (BP, CVP, HR, diuresis)
Trial: 21851025
Drug: Infusion therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion therapy controlled by transesophageal dopplerography
Trial: 21851025
Drug: Infusion therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion therapy assessed clinically
Trial: 17392668
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine analgesia (control)
Trial: 17392668
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (intravenous morphine)
Trial: 9932219
Drug: Insulin Lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin Lispro (5 min before the meal)
Trial: 9932219
Drug: Regular insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular insulin (20 min before the meal)
Trial: 8092452
Drug: midazolam, 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: midazolam, 0.2 mg/kg BW orally
Trial: 8092452
Drug: nordazepam, 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nordazepam, 0.2 mg/kg BW orally
Trial: 8092452
Drug: atropine, 0.5
RxNorm normalized name: Isopto Atropine, 0.5% ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atropine, 0.5 mg, plus promethazine, 50 mg i.m.
Trial: 8092452
Drug: atropine, 0.5
RxNorm normalized name: Isopto Atropine, 0.5% ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atropine, 0.5 mg, plus promethazine, 50 mg, plus pethidine, 0.7 mg/kg BW i.m.
Trial: 12820857
Drug: Cortisol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol (10 mg)
Trial: 11208406
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate 40 mg
Trial: 11208406
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate 80 mg
Trial: 7058754
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate 120 mg
Trial: 11208406
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate 40 mg in 3x phase
Trial: 11208406
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate 80 mg in 2x phase
Trial: 11208406
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate 80 mg in once-daily phase
Trial: 11208406
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate 120 mg in once-daily phase
Trial: 8879340
Drug: Beta‐adrenoceptor blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta‐adrenoceptor blocker (atenolol)
Trial: 1642341
Drug: Serum thiopental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum thiopental concentration of 10-30 micrograms/ml for 5 min
Trial: 1642341
Drug: Higher serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher serum thiopental concentration of 40-90 micrograms/ml
Trial: 6380114
Drug: Herbazol A
RxNorm normalized name: HERBAL MISCELLANEOUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbazol A (with antacid component)
Trial: 6380114
Drug: Herbacid B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbacid B (without antacid component)
Trial: 29351646
Drug: Postpartum training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postpartum training program (weekly supervised exercise class focusing on pelvic floor muscle strength training and daily home training)
Trial: 29693865
Drug: Sildenafil monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil monotherapy
Trial: 23348043
Drug: Exercise group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise group (EX) - core strengthening home exercise program thrice weekly for 6 weeks
Trial: 23706759
Drug: Vildagliptin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (50 mg once or twice daily)
Trial: 20502283
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg orally twice daily for 5 days at the onset of bleeding)
Trial: 18556141
Drug: Radiotherapy (RT)
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy (RT) with absorbed dose >1.0 Gy to the contralateral breast (CB)
Trial: 18556141
Drug: Radiotherapy (RT)
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy (RT) with absorbed dose to the contralateral breast (CB)
Trial: 16670154
Drug: 8% CHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% CHO solution
Trial: 12792873
Drug: Killed whole-promastigote
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Killed whole-promastigote vaccine cocktail plus BCG adjuvant
Trial: 8457502
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg of oral acetazolamide (group A)
Trial: 21058884
Drug: Auricular acupressure
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular acupressure (stimulator tapping and regular massage twice a day for 4 weeks)
Trial: 16606763
Drug: Trientine hydrochloride
RxNorm normalized name: Trientine Hydrochloride
DrugBank: Triethylenetetramine (DB06824)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Trientine hydrochloride 500 mg 2 times per day plus 50 mg of zinc 2 times per day
Trial: 16606763
Drug: Tetrathiomolybdate 20
RxNorm normalized name: Tetrathiomolybdate
DrugBank: Tetrathiomolybdate (DB05088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetrathiomolybdate 20 mg 3 times per day with meals and 20 mg 3 times per day between meals plus 50 mg of zinc 2 times per day
Trial: 10946883
Drug: Cyclical etidronate
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclical etidronate (200 mg/day for 2 weeks every 3 months)
Trial: 1428733
Drug: Vindesine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vindesine (2 mg/M2/dose) plus Prednisone (60 mg/M2/dose)
Trial: 1428733
Drug: Vincristine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine (2 mg/M2/dose) plus Prednisone (60 mg/M2/day)
Trial: 3897404
Drug: Levamisole 150
RxNorm normalized name: levamisole 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole 150 mg/day for three consecutive days for three months
Trial: 27430123
Drug: APL-130277 10
RxNorm normalized name: APL-502
DrugBank: APL-502 (DB17473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APL-130277 10 mg
Trial: 27430123
Drug: APL-130277 (dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APL-130277 (dosing up to 30 mg if needed)
Trial: 25255346
Drug: Intranasal septal
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal septal splints
Trial: 18620950
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment (IPT) with sulfadoxine-pyrimethamine and amodiaquine
Trial: 11556655
Drug: heparin 5,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: heparin 5,000 units s.c.
Trial: 9597562
Drug: Nicardipine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (40 mg)
Trial: 8165070
Drug: Prenatal dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prenatal dexamethasone (DEX) treatment (6 mg four times at 12-hour intervals)
Trial: 8165070
Drug: Prenatal dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prenatal dexamethasone (DEX) treatment combined with exogenous human surfactant therapy
Trial: 24867846
Drug: Frovatriptan 2.5
RxNorm normalized name: frovatriptan 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frovatriptan 2.5 mg (Frova)
Trial: 19244152
Drug: Psyllium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium supplementation (14 g/day for 3 months)
Trial: 17492348
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g of amino acids parenterally (Group 1)
Trial: 17492348
Drug: 150 g
RxNorm normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 g of amino acids parenterally (Group 2)
Trial: 15618054
Drug: Deferoxamine (DEF)
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deferoxamine (DEF) 4 g i.v. infusion for 8 hours starting immediately after the induction of anaesthesia (group D)
Trial: 15618054
Drug: Dextrose solution
RxNorm normalized name: Dextrose solution
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose solution as placebo for 8 hours (group C)
Trial: 15618054
Drug: Deferoxamine (DEF)
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deferoxamine (DEF) infusion in patients with lower EF (below 38%)
Trial: 15618054
Drug: Deferoxamine (DEF)
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deferoxamine (DEF) infusion in patients with higher EF (above 38%)
Trial: 10457621
Drug: Transfer-preparation letter
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transfer-preparation letter and verbal explanation
Trial: 10457621
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no transfer-preparation letter)
Trial: 8543357
Drug: Vancomycin at
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin at a concentration of 10 mg/l
Trial: 2111629
Drug: Flow setting
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flow setting A (VFG of 75 ml.min‐1.kg‐1 and VE of 150 ml.min‐1.kg‐1)
Trial: 2111629
Drug: Flow setting
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flow setting B (VFG of 110 ml.min‐1.kg‐1 and VE of 175 ml.min‐1.kg‐1)
Trial: 85583
Drug: Zinc administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc administration (0.02 mg Zn per kg of body weight in the form of zinc sulphate)
Trial: 31043691
Drug: Daily TMP/SXT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily TMP/SXT
Trial: 24015717
Drug: Glucose solutions
RxNorm normalized name: glucose Injectable Solution
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose solutions containing soy‐soluble polysaccharides (6%)
Trial: 24015717
Drug: Glucose solutions
RxNorm normalized name: glucose Injectable Solution
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose solutions containing flaxseed gum (0.7%)
Trial: 24015717
Drug: Glucose solutions
RxNorm normalized name: glucose Injectable Solution
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose solutions containing guar gum (0.23%)
Trial: 24015717
Drug: Fiber‐fortified fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber‐fortified fluid and gelled dairy‐based study treatments
Trial: 11222787
Drug: Remacemide 150
RxNorm normalized name: Remacemide
DrugBank: Remacemide (DB06458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remacemide 150 mg/d
Trial: 11222787
Drug: Remacemide 300
RxNorm normalized name: Remacemide
DrugBank: Remacemide (DB06458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remacemide 300 mg/d
Trial: 3412591
Drug: Amitriptyline (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (12.5 to 150 mg/d)
Trial: 3412591
Drug: Lorazepam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (0.5 to 6 mg/d)
Trial: 28922591
Drug: Olanzapine (2.5-20.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (2.5-20.0 mg/d)
Trial: 25593016
Drug: Docetaxel (75mg/m²
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75mg/m² IV every 21 days) with PX-866 (8mg PO daily)
Trial: 23412986
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) 3 mg/kg/d for 3 months
Trial: 23412986
Drug: Propranolol 1
RxNorm normalized name: propranolol 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 1 mg/kg for 3 months